Effects of a small molecule angiotensin IV analog on Huntington’s disease animal model
Objective: The present study was designed to test if N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide (AngIV-6a), an angiotensin IV analog, could attenuate 3-nitropropionic acid-induced Huntington’s disease-like symptoms in…Telemedicine and in-person encounters in a Huntington’s disease cohort: virtually the same
Objective: The aim of this study was to assess the impact of virtual care provision modalities (VPM) on patient satisfaction (PS) metrics for the specialized…Emerging treatments targeting DNA and RNA in Huntington’s disease: a review of future perspectives and current challenges
Objective: To review the progress made towards the development of a huntingtin (HTT) lowering strategy based on RNA and DNA and also to assess the…A case of trichotillomania as the preceding symptom of Huntington’ s diseaseand the effect of risperidone
Objective: Huntington's disease (HD) is a rare neurodegenerative disorder inherited by an autosomal dominant fashion which is most commonly characterised by choreic movement disorders. However,…Real-world effectiveness and safety of deutetrabenazine in patients with chorea associated with Huntington disease
Objective: To assess real-world effectiveness and safety of deutetrabenazine (DTBZ) for chorea associated with Huntington disease (HD). Background: Real-world evidence on the impact of DTBZ…Treatment of chorea in pediatric subjects with pallidal and thalamic deep brain stimulation
Objective: Assess the utility of deep brain stimulation (DBS) in treatment of chorea in pediatric patients. Background: While DBS has become common in treatment of…AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington’s disease minipigs up to 5 years
Objective: Our objective is to assess long-term safety of and durability of an adeno-associated viral vector serotype 5 encoding an engineered miRNA (AAV5-miHTT) targeting human…Safety and tolerability of Nilotinib in patients with Huntington’s disease
Objective: To investigate the safety and tolerability of nilotinib, an FDA-approved drug for leukemia, in individuals with Huntington’s disease (HD). Background: Previous clinical studies in…Perceptions of Palliative Care in Huntington’s Disease
Objective: This study aims to identify perceptions of palliative care in Huntington’s Disease (HD), palliative care needs of patients with HD, and at what point…An unusual cause of choreoathetosis: PRES and Goodpasture’s Syndrome
Objective: Our aim is to shed light on an usual cause of choreoathetosis in a medically complex case. Background: Goodpasture’s syndrome(GBS) is a rare autoimmune…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 11
- Next Page »